Stockscreener 앱 받기
0.9658
8.89%
-0.0942
시간 외 거래:
.96
-0.0058
-0.60%
Atyr Pharma Inc 주식(ATYR)의 최신 뉴스
Contact The Gross Law Firm by December 8, 2025 Deadline to Join Class Action Against aTyr Pharma, Inc. (ATYR) - GlobeNewswire Inc.
Detecting support and resistance levels for aTyr Pharma Inc.2025 Volatility Report & Growth-Oriented Investment Plans - newser.com
What catalysts could drive aTyr Pharma Inc. stock higherQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com
Recover Investment Losses: Class Action Initiated Against aTyr Pharma, Inc. (ATYR) - ACCESS Newswire
Shareholders that lost money on aTyr Pharma, Inc.(ATYR) Urged to Join Class ActionContact The Gross Law Firm to Learn More - PR Newswire
Is aTyr Pharma Inc. (471A) stock among top earnings playsEarnings Miss & Community Supported Trade Ideas - newser.com
Will aTyr Pharma Inc. outperform the market2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - newser.com
Statistical indicators supporting aTyr Pharma Inc.’s strengthRate Cut & Community Trade Idea Sharing - newser.com
Why aTyr Pharma Inc. stock could see breakout soonStock Surge & Scalable Portfolio Growth Ideas - newser.com
Levi & Korsinsky Urges aTyr Pharma, Inc. (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - ACCESS Newswire
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR) InvestorsContact Levi & Korsinsky Before December 8, 2025 - ACCESS Newswire
ATYR LAWSUIT ALERT: Levi & Korsinsky Notifies aTyr Pharma, Inc. InvestorsLead Plaintiff Deadline December 8, 2025 - ACCESS Newswire
aTyr Pharma Sees Significant Rebound in Premarket Trading - timothysykes.com
ATYR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of aTyr Pharma - Business Wire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr - GlobeNewswire
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages aTyr Pharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Insider Spends US$912k Buying More Shares In ATyr Pharma - 富途牛牛
Independent Director of aTyr Pharma Paul Schimmel Buys 91% More Shares - Yahoo Finance
What makes aTyr Pharma Inc. (471A) stock appealing to growth investorsWeekly Investment Summary & Safe Capital Growth Tips - newser.com
Measuring aTyr Pharma Inc.’s beta against major indices2025 Support & Resistance & Technical Confirmation Trade Alerts - newser.com
aTyr Pharma Rebounds with 7.4% Premarket Surge After Recent Decline - StocksToTrade
ATyr Pharma Faces Investor Suit Over Failed Drug Trial - Law360
Insider Buying: aTyr Pharma (NASDAQ:ATYR) Director Purchases 682,001 Shares of Stock - MarketBeat
ATyr Pharma, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ATYR - MarketScreener
aTyr Pharma, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your Rights – ATYR - FinancialContent
ATYR Investors Have Opportunity to Lead aTyr Pharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm - The AI Journal
Levi & Korsinsky Invites Investors to SueWallSt After aTyr Pharma, Inc. Stock Collapse - ACCESS Newswire
Rosen Law Firm Urges aTyr Pharma, Inc. (NASDAQ: ATYR) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights - FinancialContent
aTyr Pharma, Inc. (ATYR) Securities Class Action Deadline - GlobeNewswire
Published on: 2025-10-10 09:51:10 - newser.com
aTyr Pharma, Inc. Stock (ATYR) Opinions on Phase 3 Trial Failure - Quiver Quantitative
Trend analysis for aTyr Pharma Inc. this weekJuly 2025 Levels & Technical Buy Zone Confirmations - newser.com
aTyr Pharma Faces Legal Storm After Trial Failure - TipRanks
ATyr Pharma Rated as Overweight at Cantor Fitzgerald on Efzofitimod Expectations - MSN
What to expect from aTyr Pharma Inc. in the next 30 days2025 Market WrapUp & Stock Timing and Entry Methods - newser.com
Why aTyr Pharma Inc. (471A) stock appears on watchlistsEntry Point & Community Verified Trade Signals - newser.com
Stockholder Alert: Robbins LLP Informs aTyr Pharma, Inc. Stockholders that a Class Action Lawsuit was Filed Against the Company - Eastern Progress
Director Makes Major Investment in aTyr Pharma! - TipRanks
aTyr Pharma, Inc.’s (ATYR) Failed Drug Trial Spurs Securities Lawsuit — Hagens Berman - The Malaysian Reserve
aTyr Pharma, Inc.'s (ATYR) Failed Drug Trial Spurs Securities Lawsuit -- Hagens Berman - PR Newswire
aTyr Pharma, Inc. (ATYR) Faces Investor Scrutiny After - GlobeNewswire
Atyr pharma director Schimmel buys shares worth $911k By Investing.com - Investing.com UK
Atyr pharma director Schimmel buys shares worth $911k - Investing.com India
aTyr Pharma (NASDAQ:ATYR) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors - GlobeNewswire
aTyr Pharma Investor Sues Over Drug Study’s Endpoint Miss (1) - Bloomberg Law News
Is aTyr Pharma Inc a good long term investmentMarket Timing Techniques & Small Investment Trading Growth - earlytimes.in
Can aTyr Pharma Inc. (471A) stock sustain revenue momentumTrade Entry Report & Verified Entry Point Signals - newser.com
Evaluating aTyr Pharma Inc. with trendline analysisJuly 2025 Recap & Community Verified Trade Signals - newser.com
Why aTyr Pharma Inc. (471A) stock is favored by hedge funds2025 Institutional Moves & Weekly High Potential Alerts - newser.com
What recovery options are there for aTyr Pharma Inc.Portfolio Gains Summary & Breakout Confirmation Alerts - newser.com
Ongoing aTyr Pharma, Inc. (ATYR) Investigation: Protect Your RightsContact Levi & Korsinsky - ACCESS Newswire
ATYR stock analysis: ATYR up 19.57% today, what happened to Atyr Pharma? - Markets.com
What drives aTyr Pharma Inc stock priceShort Interest Overview & Explosive Growth Trading - earlytimes.in
ATYR ALERT: Levi & Korsinsky Investigates aTyr Pharma, Inc. For Possible Securities Fraud Violations - ACCESS Newswire
Will aTyr Pharma Inc. rebound enough to break evenQuarterly Risk Review & Free Weekly Chart Analysis and Trade Guides - newser.com
Quantitative breakdown of aTyr Pharma Inc. recent move2025 Trading Volume Trends & High Accuracy Swing Trade Signals - newser.com
1.11%
자본화:
|
볼륨(24시간):